SamanthaMaryJaglowskiMDMPH

PubMed

• Impact of chronic graft--host disease on non-relapse mortality and survival.
  Justin Jiang, Audrey M Sigmund, Qiuhong Zhao, Patrick Elder, Sumithira Vasu
  Leukemia & Lymphoma. 2024-11-01
• In Pursuit of Optimal Outcomes: A Framework for Quality Standards in Immune Effector Cell Therapy.
  Christopher E Dandoy, Joan Adams, Andrew Artz, Christopher Bredeson, Parastoo B Dahi
  Transplantation and Cellular Therapy. 2024-10-01
• SOHO State of the Art Updates and Next Questions Updates on Building Your CAR-T Cell Program.
  Timothy J Voorhees, Evandro Bezerra, Nathan Denlinger, Samantha Jaglowski, Marcos de Lima
  Clinical Lymphoma, Myeloma & Leukemia. 2024-10-01

Journal Articles

• A randomized phase II crossover study of imatinib or rituximab for cutaneous sclerosis after hematopoietic cell transplantation  
  Arai S, Pidala J, Pusic I, Chai X, Jaglowski S, Khera N, Palmer J, Chen G, Jagasia M, Mayer S, Wood W, Green M, Hyun T, Inamoto Y, Storer B, Miklos D, Shulman H, Marti..., Clin Cancer Research, 1/15/2016
• Reduced-intensity transplantation for lymphomas using haploidentical related donors versus HLA-matched sibling donors  
  Ghosh N, Karmali R, Rocha V, Ahn KW, DiGilio A, Hari PN, Vachanova V, Bacher U, Dahi P, deLima M, D’Souza A, Fenske TS, Ganguly S, Kharfan-Dajaba MA, Prestidge TD, Sav..., J Clin Oncol, 1/6/2016
• Eculizumab therapy in adults with allogeneic hematopoietic cell transplant-associated thrombotic microangiopathy  
  Vasu S, Wu H, Satoskar A, Puto M, Roddy J, Blum W, Klisovic R, Andritsos L, Hofmeister C, Benson DM, Efebera Y, Jaglowski S, Penza S, Cohen D, Devine S, Cataland S, Bone Marrow Transplant, 1/1/2016
• Allogeneic transplantation provides durabie remission in a subset of DLBCL patients relapsing after autologous transplantation  
  Fenske TS, Ahn KW, Graff TM, DiGilio A, Bashir Q, Kamble RT, Ayala E, Bacher U, Brammer JE, Cairo M, Chen A, Chen YB, Chhabra S, D’Souza A, Farooq U, Freytes C, Gangul..., Br J Haematology, 1/1/2016
• Atorvastatin for the prophylaxis of acute graft vs host disease (GVHD) in patients undergoing HLA-matched related donor hematopoietic stem cell transplantation (HSCT)  
  Efebera YA, Geyer S, Andritsos L, Vasu S, Jaglowski S, Bingman A, Blum W, Klisovic R, Hofmeister CC, Benson DM, Penza S, Elder P, Cortright K, Kitzler R, Coombes K, O’..., Biol Blood Marrow Transplant, 1/1/2016
• Endothelial chimerism in chronic sclerotic-type chronic graft-versus-host disease and GVHD-associated angiomatosis  
  Kaffenberger BH, Zhang E, Duncan JR, Jaglowski S, Klisovic RB, Devine SM, Wong HK, Gru AA, Br J Dermatol, 1/1/2016
• Tocilizumab for steroid-refractory acute graft-versus-host disease  
  Roddy JV, Haverkos BM, McBride A, Leininger KM, Jaglowski S, Penza S, Klisovic R, Blum W, Vasu S, Hofmeister CC, Benson DM, Andritsos LA, Devine SM, Efebera YA, Leuk Lymphoma, 1/1/2016
• Granulocyte colony-stimulating factor-mobilized allografts contain activated immune cell subsets associated with risk of acute and chronic graft-versus-host disease  
  Vasu S, Geyer S, Bingman A, Auletta JJ, Jaglowski S, Elder P, O’Donnell L, Bradbury H, Kitzler R, Andritsos L, Blum W, Klisovic R, Penza S, Efebera Y, Hofmeister C, Be..., Biol Blood Marrow Transplant, 1/1/2016
• Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study  
  Jaglowski SM, Jones JA, Nagar V, Flynn JM, Andritsos LA, Maddocks KJ, Woyach JA, Blum KA, Grever MR, Smucker K, Ruppert AS, Heerema NA, Lozanski G, Stefanos M, Munneke..., Blood, 1/13/2015
• Hypermorphic mutation of phospholipase C gamma-2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation  
  Liu TM, Woyach JA, Zhong Y, Lozanski A, Lozanski G, Dong S, Strattan E, Lehman A, Zhang X, Jones JA, Flynn J, Andritsos LA, Maddocks K, Jaglowski SM, Blum KA, Byrd JC,..., Blood, 1/2/2015
• A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory lymphoma  
  Maddocks K, Christian BA, Jaglowski SM, Flynn J, Jones J, Porcu P, Wei L, Jenkins C, Lozanski G, Byrd JC, Blum KA, Blood, 1/1/2015
• Externally validated predictive clinical model for untreated del(17p131) chronic lymphocytic leukemia patients  
  Stephens DM, Ruppert AS, Weirda WG, Jones JA, Woyach JA, Maddocks K, Jaglowski SM, Andritsos LA, Flynn JM, Grever MR, Lozanski G, Tam C, O’Brien S, Keating MJ, Muthusa..., Am J Hematol, 1/1/2015
• Impact of pretransplantation 18F-fluorodeoxy glucose-positron emission tomography status on outcomes after allogeneic hematopoietic cell transplantation for non-Hodgki...  
  Bachanova V, Burns LJ, Ahn KW, Laport GG, Akpek G, Kharfan-Dabaja MA, Nishihori T, Agura E, Armand P, Jaglowski SM, Cairo MS, Cashen AF, Cohen JB, D’Souza A, Freytes C..., Biol Blood Marrow Transplant, 1/1/2015
• Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia  
  Flynn J, Jones J, Johnson AJ, Andritsos L, Maddocks K, Jaglowski S, Hesler J, Grever MR, Im E, Zhou H Zhu Y, Zhang D, Small K, Bannerji R, Byrd JC, Leukemia, 1/1/2015
• miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton’s tyrosine kinase inhibition with ibrutinib  
  Guinn D, Ruppert AS, Maddocks K, Jaglowski S, Gordon A, Lin TS, Larson R, Marcucci G, Hertlein E, Woyach J, Johnson AJ, Byrd JC, Leukemia, 1/1/2015
• Etiology of ibrutinib discontinuation and outcomes in patients with chronic lymphocytic leukemia  
  Maddocks KJ, Ruppert AS, Lozanski G, Heerema NA, Zhao W, Abruzzo L, Lozanski A, Davis M, Gordon A, Smith LL, Mantel R, Jones JA, Flynn JM, Jaglowski SM, Andritsos LA, ..., JAMA Oncol, 1/1/2015
• Health related quality of life in patients that develop bronchiolitis obliterans syndrome following allogeneic stem cell transplantation  
  Amin E, Phillips G, Elder P, Jaglowski S, Devine S, Wood K, Bone Marrow Transplant, 1/1/2015
• A phase 1 study of vorinostat maintenance after autologous transplant in high-risk lymphoma  
  Hofmeister CC, Williams N, Geyer S, Hade EM, Bowers MA, Earl CT, Vaughn J, Bingman A, Humphries K, Lozanski G, Baiocchi RA, Jaglowski SM, Blum K, Porcu P, Flynn J, Pen..., Leuk Lymphoma, 1/1/2015
• Lower dose of antithymocyte globulin (ATG) does not increase graft-versus-host disease (GVHD) in patients undergoing reduced-intensity conditioning (RIC) allogeneic he...  
  Salem G, Ruppert AS, Elder P, Hofmeister CC, Benson DM, Penza S, Andritsos L, Klisovic R, Vasu S, Blum W, Devine SM, Jaglowski S, Efebera YA, Leuk Lymphoma, 1/1/2015
• Resistance mechanisms for the Bruton’s tyrosine kinase inhibitor ibrutinib  
  Woyach JA, Furman RR, Liu TM, Ozer HG, Zapatka M, Ruppert AS, Xue L, LiDH, Steggerda SM, Versele M, Dave SS, Zhang J, Yilmaz AS, Jaglowski SM, Blum KA, Lozanski A, Loz..., N Engl J Med, 1/12/2014
• Transplant for CLL: still an option?  
  Jaglowski SM, Blood, 1/1/2014
• Graft-versus-Host disease: Why Haven’t We Made More Progress?  
  Jaglowski SM, Devine SM, Curr Opinion Hematol, 1/1/2014
• Ibrutinib treatment ameliorates murine chronic graft-versus-host disease  
  Dubovsky JA, Flynn R, Du J, Harrington DK, Zhong Y, Kaffenberger B, Yang C, Towns WH, Lehman A, Johnson AJ, Muthusamy N, Devine SM, Jaglowski S, Serody JS, Murphy WJ, ..., J Clin Invest, 1/1/2014
• The hematopoietic stem cell transplant comorbidity index can predict for 30-day readmission following autologous stem cell transplant for lymphoma and multiple myeloma  
  Jaglowski SM, Ruppert AS, Hofmeister CC, Elder P, Blum W, Klisovic R, Vasu S, Penza S, Efebera YA, Benson DM, Devine SM, Andritsos LA, Bone Marrow Transplant, 1/1/2014
• Impact of age on quality of life, functional status, and survival in patients with chronic graft-versus-host disease  
  El Jawahri A, Pidala J, Inamoto Y, Chai X, Khera N, Wood WA, Cutler C, Arora M, Carpenter PA, Palmer J, Flowers M, Weisdorf D, Pavletic S, Jaglowski S, Jagasia M, Lee ..., Biol Blood Marrow Transplant, 1/1/2014
• Join now to see all

Abstracts/Posters

• Preliminary Clinical Results from a Phase 1 Study of ACTR707 in Combination with Rituximab in Subjects with Relapsed or Refractory CD20+ non-Hodgkin Lymphoma
  Samantha Jaglowski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Effect of Early Post Transplantation Tacrolimus Concentration on the Risk of Acute Graft-Versus-Host Disease in Allogenic Stem Cell Transplantation
  Samantha Jaglowski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Impact of Tisagenlecleucel Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Attributes on Clinical Outcomes in Adults with Relapsed or Refractory Diffuse Large B...
  Samantha Jaglowski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• A Phase 1 Study of ACTR087 in Combination with Rituximab, in Subjects with Relapsed or Refractory CD20-Positive B-Cell Lymphoma
  Samantha Jaglowski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Results of a Phase I Study of Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma
  Samantha Jaglowski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Selinexor Combined with Ibrutinib Demonstrates Tolerability and Efficacy in Advanced B-Cell Malignancies: A Phase I Study
  Samantha Jaglowski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Correlative Analyses of Patient and Clinical Characteristics Associated with Efficacy in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Pat...
  Samantha Jaglowski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Phase I Dose-Escalation Study of Venetoclax Plus BEAM Followed By Autologous Stem Cell Transplant (ASCT) for Chemoresistant or High-Risk Relapsed/Refractory Non-Hodgki...
  Samantha Jaglowski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Correlation of Bridging and Lymphodepleting Chemotherapy with Clinical Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Tisagen...
  Samantha Jaglowski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) With Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Results of the Phase...
  Samantha Jaglowski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after Programmed Cell Death 1 (PD-1) / Programmed Cell Death Ligand 1 (PD-L1) Blockade for Classic...
  Samantha Jaglowski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Multicenter Open-Label Phase 1b/2 Study of Ibrutinib in Steroid-Dependent/Refractory Chronic Graft Versus Host Disease (cGVHD)
  Miklos D, Cutler C, Arora M, Waller E, Jagasia M, Nakamura R, Blazar B, Juretic M, Li Y, Dubovsky J, James D, Styles L, Jaglowski S, Bone Marrow Transplant, 1/1/2016
• Antithymocyte Globulin (ATG) 4.5 vs 6.0 mg/kg in Reduced Instnsity Conditioning (RIC) Allogeneic Hematopoietic Stem Cell Transplant (alloHSCT)
  Issa H, Ruppert AS, Elder P, Hofmeister CC, Benson DM, Penza S, Andritsos LA, Klisovic R, Vasu S, Blum W, Jaglowski S, Devine SM, Efebera YA, ASBMT Annual Meeting, 1/1/2016
• Preliminary Safety and Efficacy Data Using CDX-301 (Flt3 ligand)as a Sole Agent to Mobilize Hematopoietic Cells Prior to HLA-Matched Sibling Donor Transplantation
  Jaglowski S, Waller EK, Kindwall-Keller TL, McCarty JM, Dugan M, Yellin M, Davis T, Devine SM, Biol Blood Marrow Transplant, 1/1/2016
• Preliminary Safety and Efficacy Data Using CDX-301 (Flt3 ligand)as a Sole Agent to Mobilize Hematopoietic Cells Prior to HLA-Matched Sibling Donor Transplantation
  Jaglowski S, Waller EK, Kindwall-Keller TL, McCarty JM, Dugan M, Yellin M, Davis T, Devine SM, ASBMT Annual Meeting, 1/1/2016
• Significant Impact of Mobilization Strategy on the Cellular Composition of Donor Allografts
  Rotta M, Wei L, Kitzler R, Bradbury H, Bingman A, Vasu S, Jaglowski S, Blum W, Klisovic R, Penza S, Andritsos LA, Efebera YA, Lozanski G, Devine SM, Biol Blood Marrow Transplant, 1/1/2016
• Significant Impact of Mobilization Strategy on the Cellular Composition of Donor Allografts
  Rotta M, Wei L, Kitzler R, Bradbury H, Bingman A, Vasu S, Jaglowski S, Blum W, Klisovic R, Penza S, Andritsos LA, Efebera YA, Lozanski G, Devine SM, ASBMT Annual Meeting, 1/1/2016
• Multicenter Open-Label Phase 1b/2 Study of Ibrutinib in Steroid-Dependent/Refractory Chronic Graft Versus Host Disease (cGVHD)
  Miklos D, Cutler C, Arora M, Waller E, Jagasia M, Nakamura R, Blazar B, Juretic M, Li Y, Dubovsky J, James D, Styles L, Jaglowski S, EBMT Annual Meeting, 1/1/2016
• Geriatric Assessment Metrics Are Associated with Hospital Length of Stay in Pre-Bone Marrow Transplant Myeloma Patients
  Rosko AE, Hofmeister CC, Efebera YA, Benson DM, Sborov DW, Jaglowski S, Devine S, Wildes TM, Gillahan J, Jones D, Huang Y, Burd CE, ASH Annual Meeting, 1/1/2015
• Safety and Efficacy of Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Who Have Undergone Prior Allogeneic Stem ...
  Miklos DB, Coutre S, O’Brien S, Byrd JC, Hillmen P, Brown JR, Dyer M, Mato AR, Keating M, Zhou C, Fardis M, Styles L, Jaglowski S, ASBMT Annual Meeting, 1/1/2015
• A Randomized Phase II Study of Imatinib and Rituximab for Cutaneous Sclerosis after Allogeneic Hematopoietic Stem Cell Transplantation
  Arai S, Pidala J, Pusic I, Chai X, Jaglowski S, Palmer J, Chen GL, Khera N, Mayer S, Jagasia MH, Wood WA, Martin PJ, Inamoto Y, Miklos DB, Lee SJ, Flowers MED, Biol Blood Marrow Transplant, 1/1/2015
• A Randomized Phase II Study of Imatinib and Rituximab for Cutaneous Sclerosis after Allogeneic Hematopoietic Stem Cell Transplantation
  Arai S, Pidala J, Pusic I, Chai X, Jaglowski S, Palmer J, Chen GL, Khera N, Mayer S, Jagasia MH, Wood WA, Martin PJ, Inamoto Y, Miklos DB, Lee SJ, Flowers MED, ASBMT Annual Meeting, 1/1/2015
• A Phase I Study of Milatuzumab for Prevention of Acute Graft Versus Host Disease Following Reduced-Intensity Conditioning Allogeneic Stem Cell Transplant in Patients w...
  Haverkos B, Cortright K, Andritsos LA, Blum W, Klisovic R, Vasu S, Goldenberg DM, Wegener W, Devine SM, Jaglowski S, Biol Blood Marrow Transplant, 1/1/2015
• A Phase I Study of Milatuzumab for Prevention of Acute Graft Versus Host Disease Following Reduced-Intensity Conditioning Allogeneic Stem Cell Transplant in Patients w...
  Haverkos B, Cortright K, Andritsos LA, Blum W, Klisovic R, Vasu S, Goldenberg DM, Wegener W, Devine SM, Jaglowski S, ASBMT Annual Meeting, 1/1/2015
• A multicenter open-label phase 1b/2 study of ibrutinib in steroid dependent or refractory chronic graft versus host disease (cGVHD)
  Miklos DB, Arora M, Cutler CS, Nakamura R, Juretic M, Li Y, Styles LA, James DF, Jaglowski SM, J Clin Oncol, 1/1/2015
• Join now to see all

Lectures

• Axicabtagene Ciloleucel in the Real World: Outcomes and Predictors of Response, Resistance and Toxicity 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Sustained Disease Control for Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: An Updated Analysis of Juliet, a Global Pivotal Phase 2 Trial o... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Phase II Study Evaluating the Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem and Progenitor Cells for Allogeneic Hematopoietic Cell Tr... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Stem Cell Transplantation for the General Internist 
  The Ohio State University, Columbus, OH - 1/9/2015
• A Phase Ib/II Multi-Center Study of Ibrutinib in Steroid Dependent/Refractory Chronic Graft-versus-Host Disease 
  Grapevine, TX - 1/25/2014
• Stem Cell Transplantation 
  The Ohio State University, Columbus, OH - 1/22/2014
• Graft-versus-Host Disease 
  The Ohio State University, Columbus, OH - 1/3/2014
• Ask the Expert: Bone Marrow Transplant 
  Columbus, OH - 1/14/2013
• Non-Hodgkin’s Lymphoma 
  The Ohio State University, Columbus, OH - 1/12/2013
• Project Cancer Education 
  Arthur G. James Cancer Hospital, Columbus, OH, 2009, 2010, 2011, 2012 - 1/22/2012
• Aggressive Lymphomas 
  The Ohio State University, Columbus, OH - 1/22/2012
• Salvage Regimens with Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era: the CORAL Study 
  The Ohio State University, Columbus, OH - 1/5/2011
• Late Effects of Hematopoietic Stem Cell Transplant 
  The Ohio State University, Columbus, OH - 1/1/2011
• Lovenox Hurts 
  The Ohio State University College of Medicine and Public Health, Columbus, OH - 1/16/2009
• Join now to see all

Other

• The Effects of y-Tocopheryl Quinone on HeLa Cervical Carcinoma Cells (Senior thesis) 
  Jaglowski SM, The Ohio State University